Aptose Up 20% In US Premarket After Update On Its Frontline Triple Drug Therapy With Tuspetinib
In This Article:
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, was a
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.